Every material Form 8-K Vivani Medical, Inc. has filed with the SEC since September 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vivani Medical said its wholly owned subsidiary Cortigent will merge into a ClearOne subsidiary under a previously announced agreement. Closing still depends on final regulatory approval, and the parties expect it to occur shortly after that approval is received.
Vivani had anticipated the Transaction closing in October 2026.
Closing remains subject to receipt of final regulatory approval.
The filing gives no deal value, financial terms or regulatory timeline.
Vivani Medical filed a Form 8-K furnishing a slide presentation (Exhibit 99.1) dated October 29, 2026, that it uses at investment conferences to update on its business. The filing states the slides speak only as of their date, the company disclaims any duty to update them, and the material is not deemed filed under the Exchange Act. The filing itself contains no financial results, guidance, or new transaction terms.
Regulation FD disclosure under Item 7.01 provides slide presentation as Exhibit 99.1
Presentation is dated October 29, 2026, and speaks only as of that date
Filing includes no revenue, earnings, or guidance figures in the text provided
Vivani Medical disclosed in a Regulation FD filing that it expects pricing and closing of the previously announced merger of its subsidiary Cortigent into a ClearOne subsidiary to occur in October 2026. The filing reiterates the transaction structure but gives no financial terms, and it carries a risk that the deal may not be completed.
Cortigent, a wholly owned Vivani subsidiary, will merge with and into CLRO Merger Sub, Inc., becoming a wholly owned subsidiary of ClearOne, Inc.
Vivani anticipates pricing and closing of the Transaction in October 2026.
Forward-looking statements cite the Company's inability to consummate the Transaction as a key risk.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vivani Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →